Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804146 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL16967371 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL3886489 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL5862033 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL804233 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7415779 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL5860905 | 0.98 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7710838 | 0.85 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4676515 | 0.85 | ALOX5 (0.53) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL25178201 | 0.83 | ESR1 (0.46) | LMNAHIF1AKDM4ECYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042293-B9 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1042293-B1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1448564-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003044021-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1042293-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Amgen Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1999032448-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | DPP4 301/4885LMNA 3990/4885ADRA2A 1889/4885 |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | IL1A, IL1B, IL6 | DPP4 214/4885LMNA 3641/4885ADRA2A 521/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | DPP4 361/4885LMNA 2575/4885ADRA2A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.